BMS criticises Scottish regulator over Opdivo skin cancer ‘no’
March 7, 2016Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo
Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …
AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL
March 7, 2016Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica
Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …
Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
March 7, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …
Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo
March 7, 2016Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo
Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …
Novo Nordisk reports five-year Victoza cardiovascular safety data
March 7, 2016Research and Development, Sales and Marketing Novo Nordisk, Victoza
Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …
FDA approves CSL Behring’s new haemophilia B treatment
March 7, 2016Research and Development, Sales and Marketing CSL Behring, haemophilia
The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …
Novartis says its psoriasis drug bests Janssen’s in comparison study
March 7, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara
Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …
Teva suffers EpiPen generic setback after FDA rejection
March 4, 2016Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection
The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …
BioMarin reports positive early-stage results for trial drug to treat CLN2 disease
March 4, 2016Medical Communications
Biotechnology firm BioMarin Pharmaceutical has announced positive results from early stage trial for drug to treat neurodegenerative disease in children. …
Merck & Pfizer tie-up with Verastem to develop ovarian cancer drug
March 4, 2016Medical Communications
German drug major Merck along with Pfizer has joined forces with Verastem to develop the trial drug candidate avelumab to …
Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment
March 4, 2016Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2
Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …
Almost half of US physicians will prescribe more biosimilars, according to survey
March 4, 2016Medical Communications Obama, US, biosimilar, patent, prescribing
New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …
Baxalta seeks European marketing rights for haemophilia drug
March 3, 2016Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta
Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
Merck announces drug discovery collaboration with European Molecular Biology Laboratory
March 3, 2016Research and Development Cancer, Merck, biomarkers
Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …
Amgen sues Novartis over Enbrel biosimilar
March 3, 2016Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
Valeant company group chairman and executive vice president resigns
March 3, 2016Medical Communications, Sales and Marketing Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
CHMP recommends Sanofi’s two-dose schedule HPV vaccine
March 3, 2016Research and Development HPV vaccine, MSD, Sanofi Pasteur
Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Bill Griffiths joins NDA group as general manager UK
March 2, 2016Medical Communications NDA Group
Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board. …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
